Claims for Patent: 7,914,542

Summary for Patent: 7,914,542

Title:	Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
Abstract:	Devices, systems and methods for compressing, cutting, incising, reconfiguring, remodeling, attaching, repositioning, supporting, dislocating or altering the composition of tissues or anatomical structures to alter their positional or force relationship to other tissues or anatomical structures. In some applications, the invention may be used to used to improve patency or fluid flow through a body lumen or cavity (e.g., to limit constriction of the urethra by an enlarged prostate gland).
Inventor(s):	Lamson; Theodore Charles (Pleasanton, CA), Makower; Joshua (Los Altos, CA), Catanese, III; Joseph (San Leandro, CA), Welch; Jacqueline Nerney (Pacifica, CA), Walke; Amrish Jayprakash (Santa Clara, CA), Vidal; Claude (Santa Barbara, CA), Redmond; Russell J. (Goleta, CA), Collinson; Michael (Goleta, CA)
Assignee:	Neotract, Inc. (Pleastanton, CA)
Application Number:	11/838,036
Patent Claims:	1. A method for treating a condition in a human or animal subject wherein the prostate gland is causing undesirable constriction of the urethra, said method comprising the steps of: A) inserting an introducer device into the subject's body; B) advancing a cutting device from the introducer device; C) using the cutting device to cut at least a portion of the prostate such that the constriction of the urethra is lessened; placing a first anchor at a first location on, in or adjacent to the prostate; placing a second anchor at a second location on, in or adjacent to the prostate; and placing a connecting member between the first and second anchors, said connecting member drawing at least one of said first and second anchors toward the other thereby compressing at least a portion of the prostate. 2. A method according to claim 1 wherein the introducer device inserted in Step A comprises a scope lumen and a working lumen and wherein a scope is inserted into the scope lumen and the cutting device is advanced through the working lumen. 3. A method according to claim 2 further comprising the step of using the scope to view at least a portion of the performance of the method. 4. A method according to claim 1 wherein Step A comprises inserting the introducer into the urethra and advancing it to a position within the urethra where the urethra is substantially surrounded by the prostate gland. 5. A method according to claim 1 wherein Step A comprises inserting the introducer into the urethra and advancing the introducer to a position within the urethra distal to the prostate gland. 6. A method according to 1 wherein Step A comprises inserting the introducer into the urethra and advancing the introducer into the urinary bladder. 7. A method according to claim 1 wherein Step A comprises inserting the introducer to a position within the urethra and wherein Steps B and C comprise forming an opening in the wall of the urethra, advancing either the introducer or the cutting apparatus though the opening formed in the wall of the urethra and thereafter causing the cutting apparatus to form a cut that extends through the capsule of the prostate gland. 8. A method according to claim 7 wherein the opening formed in the wall of the urethra is no greater than 2 mm in its greatest cross-dimension. 9. A method according to claim 7 further comprising the step of closing the opening formed in the urethra. 10. A method according to claim 1 wherein Step B comprises advancing the cutting device into the prostate gland. 11. A method according to claim 1 wherein Step B comprises advancing a guide to a position within or near the prostate and advancing the cutting device over or through said guide. 12. A method according to claim 11 wherein the guide comprises a guidewire and wherein the cutting device comprises a guidewire lumen that facilitates advancement of the cutting device over the guidewire. 13. A method according to claim 11 further comprising the step of anchoring the guide. 14. A method according to claim 13 wherein the step of anchoring the guide comprises anchoring a distal portion of the guide. 15. A method according to claim 13 wherein the guide is advanced through the prostate into the urinary bladder and wherein the guide is anchored in a way that deters a distal portion of the guide from being pulled out of the urinary bladder. 16. A method according to claim 1 wherein Step C comprises using the cutting device to form a subcapsular cut within the prostate gland. 17. A method according to claim 1 wherein Step C comprises using the cutting device to form a cut through the capsule of the prostate gland. 18. A method according to claim 1 wherein Step C comprises using the cutting device to form a cut that extends through subcapsular prostate tissue and through the capsule of the prostate gland. 19. A method according to claim 1 further comprising administering a local, regional or general anesthetic to the subject. 20. A method according to claim 19 wherein a local anesthetic is injected into the prostate before performance of Step C. 21. A method according to claim 1 wherein the cutting device comprises an elongate shaft and a cutting element that is deployable from the shaft. 22. A method according to claim 21 wherein Step C comprises causing the cutting member to emit energy to facilitate formation of said cut. 23. A method according to claim 22 wherein the cutting member is caused to emit radiofrequency energy. 24. A method according to claim 1 further comprising the step of maintaining separation of opposing surface of the cut for at least a period of time after formation of the cut. 25. A method according to claim 24 wherein the step of maintaining separation of opposing surface of the cut for at least a period of time after formation of the cut comprises implanting space occupying matter within the cut. 26. A method according to claim 25 wherein the space occupying matter is substantially resorbable. 27. A method according to claim 26 wherein the space occupying matter comprises is not substantially resorbable. 28. A method according to claim 24 wherein the step of maintaining separation of opposing surface of the cut for at least a period of time after formation of the cut comprises implanting a device within the cut. 29. A method according to claim 25 wherein the device implanted within the cut is substantially resorbable. 30. A method according to claim 26 wherein the device implanted within the cut is not substantially resorbable. 31. A method according to claim 1 further comprising the step of delivering a therapeutic substance to a location within or near the prostate gland. 32. A method according to claim 31 wherein the therapeutic substance is selected from the group consisting of: hemostatic agents; antimicrobial agents; antibiotics; antifungals; antiprotozoals; antivirals; antimicrobial metals; hemostatic and/or vasoconstricting agents; pseudoephedrine; xylometazoline; oxymetazoline; phenylephrine; epinephrine; cocaine; local anesthetic agents; lidocaine; cocaine; bupivacaine; hormones; anti-inflammatory agents; corticosteroids; non-steroidal anti-inflammatory agents; hormonally active agents; agents that enhance potency; substances that dissolve, degrade, cut, break, weaken, soften, modify or remodel connective tissue or other tissue; enzymes; collagenase; trypsin; EDTA; trypsin combined with EDTA; hyaluronidase; tosyllysylchloromethane (TLCM)); chemotherapeutic or antineoplastic agents; substances that prevent adhesion formation; hyaluronic acid gel; space occupying substances; substances that promote desired tissue ingrowth into an anchoring device or other implanted device; substances that promote or facilitate epithelialization; substances that create a coagulative lesion which is subsequently resorbed causing the tissue to shrink, substances that cause the prostate to decrease in size; phytochemicals that cause the prostate to decrease in size; alpha-1a-adrenergic receptor blocking agents; 5-alpha-reductase inhibitors; smooth muscle relaxants and agents that inhibit the conversion of testosterone to dihydrotestosterone. 33. A method according to claim 31 wherein the step of delivering a therapeutic substance to a location within or near the prostate gland comprises injecting said therapeutic substance into or near the prostate gland. 34. A method according to claim 31 wherein the step of delivering a therapeutic substance to a location within or near the prostate gland comprises placing a substance eluting implant in or near the prostate gland. 35. A method according to claim 34 wherein the substance eluting implant comprises a substance eluting device. 36. A method according to claim 34 wherein the substance eluting implant comprises a substance eluting material. 37. A method according to claim 34 wherein the substance eluting implant is positioned within the cut. 38. A method according to claim 37 wherein the substance eluting implant is further operative to maintain separation of opposing surface of the cut for at least a period of time after formation of the cut. 39. A method according to claim 1 further comprising the step of: forming a lesion within the tissue which subsequently causes shrinkage of the tissue. 40. A method according to claim 39 wherein a coagulative lesion is formed by heating the tissue. 41. A method according to claim 40 wherein the coagulative lesion subsequently becomes resorbed thereby causing the tissue to shrink. 42. A method according to claim 1 further comprising the step of implanting at least one tissue compressing device to compresses the prostate in a manner that lessens constriction of the urethra. 43. A method according to claim 1 wherein Step C comprises using the cutting device to form a cut within the capsule of the prostate gland.

Details for Patent 7,914,542

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2025-05-20
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2025-05-20
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2025-05-20
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2025-05-20
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2025-05-20